Skip to content
Screener

G&A at other companies

Guardant Health logo
Guardant HealthGH
$57.93M+23.4%
Myriad Genetics logo
Myriad GeneticsMYGN
$62.2M-6.5%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$20.98M+20.6%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$10.13M+25.2%
Lumexa Imaging Holdings, Inc. logo
Lumexa Imaging Holdings, Inc.LMRI
$20.34M+16.3%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$27.68M+9.5%

Segments

By segment

See full
Reportable Segment$37.81M+31.7%

Other financials

Income statement

See full
Revenue$44.7M+25.7%
Operating income-$173.8M-9.4%
Net income-$110.2M+3.3%
EPS (diluted)-$2.56+19.5%

Balance sheet

See full
Cash & equivalents$62.6M-52.1%
Total debt$91.3M+46.9%
Total equity$2.5B+9.9%
Total assets$2.8B+5.2%

Cash flow

See full
Operating cash flow-$80.7M-4.9%
CapEx$432.0K+17.1%
Free cash flow-$81.2M-4.9%

Valuation

See full
Market cap$2.72B+129%
Enterprise value$2.75B+145%
P/S16.5×+7.6×

Profitability

See full
Operating margin-338.4%-74.4pp
Net margin-236.9%-52.1pp
FCF margin-179.2%-46.7pp

Returns & leverage

See full
Return on equity-16.1%-1.3pp
Debt / equity0.0×
Current ratio10.9×+1.7×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: GRAIL, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054307
Line itemThree Months Ended / June 30,2026Three Months Ended / June 30,2025Six Months Ended / June 30,2026Six Months Ended / June 30,2025
Cost of revenue — amortization of intangible assets33,47233,47266,94466,944
Research and development47,42946,62695,450100,251
Sales and marketing37,65728,53968,32563,518
General and administrative50,70837,91493,47782,988
Intangible and other assets impairment25,42328,00025,42328,000
Total costs and operating expenses218,470194,398395,020379,842
Loss from operations(173,783)(158,854)(309,548)(312,461)
Other income:

Item 1. Financial Statements

FAQ

What is GRAIL, Inc.'s G&A?
GRAIL, Inc. (GRAL) reported G&A of $50.71M in Q2 2026.
How has GRAIL, Inc.'s G&A changed year-over-year?
GRAIL, Inc.'s G&A increased by 33.7% year-over-year, from $37.91M to $50.71M.
What is the long-term trend for GRAIL, Inc.'s G&A?
Over 3 years (2022 to 2025), GRAIL, Inc.'s G&A has grown at a -3.0% compound annual growth rate (CAGR), from $174.11M to $159.1M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about GRAIL, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude